Core One Labs (COOL.C) announced that their wholly-owned subsidiary Vocan Biotechnologies are in the final stages of completing their provisional patent application for the protection of their proprietary biosynthetic…
Vocan
Core One Labs (COOL.C) announced they have entered into a letter of intent (LOI) with Lobe Sciences (LOBE.C) to explore the formation of a joint venture (JV) involving the…
Core One Labs (COOL.C) subsidiary, Vocan Biotechnologies, and the University of British Columbia (UBC), came to terms on a collaborative research agreement today, according to a press release. The…
Core One Labs’ (COOL.C) wholly-owned subsidiary Vocan Biotechnologies has initiated the design and engineering of a proprietary enzymatic production system for API-grade N,N-dimethyltryptamine, commonly known as DMT. DMT, also…
Core One Labs (COOL.C) subsidiary Vocan Biotechnologies finished putting together the required equipment to start artificially producing psilocybin today, according to a press release. Acquired in December, Vocan has…
Core One’s objective in developing the psilocybin thinstrips is to assist with the delivery of revolutionary psychedelic treatment methods to address mental health conditions such as depression, anxiety and…
“This transaction will significantly enhance Core One Labs’ ability to innovate our psychedelic drug development program,” stated Joel Shacker, CEO of Core Labs….